Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, Singh A, van der Zwan W, Severi S,
Keywords: biomarker, PRRT, prediction, NETest, PPQ, CgA, personalized medicine,
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,
Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,
Introduction: A
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Nowicki M, Kolasińska-Ćwikła A, Lewczuk A, Sankowski A, Bodei L,
Keywords: intra-arterial PRRT, progressive GEP-NENs, liver dominant,
Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: de Mestier L
Authors: De Mestier L, Cros J, Hentic O, Legoux J, Muller N,
Keywords: chemotherapy, tumor response, tolerance, pfs,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Yao J
Authors: Yao J, Fazio N, Pavel M, Strosberg J, Bergsland E,
Keywords: PDR001, immunotherapy, NET,